WINNIPEG, MANITOBA -- (Marketwired) -- 08/19/13 -- Editors note: There is one photo associated with this press release.
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce five new SCOUT DS® publications in peer-reviewed journals since April 2013. These studies include research demonstrating the superiority of the SCOUT DS® system when compared to random capillary glucose in an at-risk population, published in Diabetes Research and Clinical Practice in April 2013.
"The recent publication of a number of SCOUT DS® studies in well-respected, peer-reviewed journals, highlights the increasing scientific evidence in support of this product, the world's first non-invasive diabetes screening system," said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "The SCOUT DS® is designed to provide a highly sensitive and convenient method for screening of pre-diabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin and we are pleased to see the supporting scientific evidence continue to build."
Recent SCOUT DS® publications are as follows:
1. Tentolouis N. et al. Screening for HbA1c-defined prediabetes and diabetes in an at-risk Greek population: Performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy. Diabetes Research and Clinical Practice 2013: 100(1): 39-45.
2. Cleary PA. et al. Clinical and Technical Factors Associated with Skin Intrinsic Fluorescence in Subjects with Type 1 Diabetes from the DCCT/EDIC Study. Diabetes Technology and Therapeutics 2013:15(6): 466-474.
3. Orchard TJ. et al. The Association of Skin-Intrinsic Fluorescence With Type 1 Diabetes Complications in the DCCT/EDIC Study. (Published online ahead of print June 28, 2013 Diabetes Care. Doi: 10.2337/dc12-2661.
4. Olson BP. et al. Noninvasive Skin Fluorescence Spectroscopy Is Comparable to Hemoglobin A1c and Fasting Plasma Glucose for Detection of Abnormal Glucose Tolerance. Journal of Diabetes Science and Technology 2013: 7(4): 990-1000.
5. Shah S. et al. Advanced glycation endproducts in children with diabetes. (Published online ahead of print August 5, 2013) Journal of Pediatrics. Doi: 10.1016/jpeds.2013.06.044.
In addition to these current publications, the clinical and scientific evidence underlying the SCOUT DS® has been developed in a number of clinical studies, across more than 30 clinical sites and over 3,000 patients.
Most Popular Stories
- NSA Defends Global Cellphone Tracking Legality
- Top Websites for U.S. Hispanics
- Ad Counts Rise in 2013 for Hispanic Magazines
- Networks Vie for U.S. Hispanic TV Viewers
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Apple Activates Customer-Tracking iBeacon
- A Biography of Jonathan Ive, Apple's Creative Chief
- 2013 Tech Gift Guide: iPad Mini Still Hot; Chromecast a Great Low-Cost Option
- Dell Offers Undisclosed Number of Employee Buyouts
- Authorities Close to Deal with JPMorgan Chase over Madoff Response